Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EPS (Weighted Average and Diluted) (2019 - 2025)

Collegium Pharmaceutical has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.46 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.46 for Q4 2025, up 27.78% from a year ago — trailing twelve months through Dec 2025 was $1.71 (down 8.06% YoY), and the annual figure for FY2025 was $1.73, down 6.99%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.46 at Collegium Pharmaceutical, down from $0.84 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for COLL hit a ceiling of $1.79 in Q2 2021 and a floor of -$0.73 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.34 (2023), compared with a mean of $0.29.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 465.0% in 2021 and later skyrocketed 5200.0% in 2023.
  • Collegium Pharmaceutical's EPS (Weighted Average and Diluted) stood at -$0.73 in 2021, then soared by 71.23% to -$0.21 in 2022, then skyrocketed by 490.48% to $0.82 in 2023, then plummeted by 56.1% to $0.36 in 2024, then increased by 27.78% to $0.46 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.46 (Q4 2025), $0.84 (Q3 2025), and $0.34 (Q2 2025) per Business Quant data.